[유상증자 모니터] 'CDMO 부진' 지놈앤컴퍼니, 화장품 사업 힘준다

Genome & Company is shifting its primary growth engine to the consumer cosmetics brand UIQ to mitigate financial instability caused by stagnant CDMO performance. This transition underscores a critical biotech survival strategy of securing immediate liquidity through consumer-facing products to fund high-risk clinical R&D.